Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September
August 30 2017 - 7:00AM
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced
that senior management will present at three upcoming
healthcare investor conferences.
Conference Details:
Event: 2017 Wells Fargo Securities Healthcare Conference
Date/Time: Wednesday, September 6
at 3:00 p.m. EDTLocation: Boston, MA
Event: Ladenburg Thalmann 2017 Healthcare Conference Date/Time:
Tuesday, September 26
at 12:00 p.m. EDTLocation: New York, NY
Event: Cantor Fitzgerald Global Healthcare ConferenceDate/Time:
Wednesday, September 27 at 9:10 a.m. EDT Location: New York,
NY
A live webcast of the fireside chat at Wells Fargo as well as
the presentation at Ladenburg Thalmann may be accessed from
the News & Events section of the Bellicum website.
Archived versions of the webcasts will be available for replay for
at least two weeks following the events.
About Bellicum
Pharmaceuticals Bellicum is a clinical stage
biopharmaceutical company focused on discovering and developing
cellular immunotherapies for cancers and orphan inherited blood
disorders. Bellicum is using its proprietary Chemical Induction of
Dimerization (CID) technology platform to engineer and control
components of the immune system. Bellicum is developing
next-generation product candidates in some of the most important
areas of cellular immunotherapy, including hematopoietic stem cell
transplantation (HSCT), and CAR T and TCR cell therapies. More
information can be found at www.bellicum.com.
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
Media:
BMC Communications
Brad Miles
646-513-3125
bmiles@bmccommunications.com
Source: Bellicum Pharmaceuticals
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Sep 2023 to Sep 2024